Tharimmune (THAR)

• Market cap: $22.4M
• 1 day: -0.67%
• 5 days: -5.75%
• 1 month: 3.87%
• 3 months: 136%
• 6 months: 70.52%
• Year to date: 43.9%
• 1 year: 3.51%
• 5 years: -99.77%
• 10 years: -99.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3